A Novel Two-Component VLP Technology for the Development of Vaccines Against Respiratory Viruses

Time: 4:15 pm
day: Day One Morning


  • Vaccine technology covering an RSV/hMPV bivalent vaccine as well as a SARS2 candidate which is in Ph1 testing now in Australia
  • Advantages of computational protein design to better inform antigen formulation and to achieve higher efficacy rates